PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Drugs
1449163365	rs9923231	PMID:29273767	VKORC1	Allele T is not associated with risk of Stroke when treated with Vitamin K antagonists in people with Atrial Fibrillation as compared to allele G.	no	= 0.159	33		Unknown	Efficacy	false	No association was seen between this SNP and risk for early ischemic stroke (within 2 years under vitamin K antagonist (VKA) treatment). Please note that alleles have been complemented to the plus chromosomal strand.	Vitamin K antagonists
1452487065	rs10849757	PMCID:PMC11106472	COQ5	Genotypes AA + AG is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Stroke as compared to genotype GG.	yes	< 0.01	56	632	East Asian	Efficacy	false	"""Patients carrying the TT genotype of rs11548336 and A allele of rs10849757 had a 1.9-fold (95% CI: 1.1–3.5) and 3.3-fold (95% CI: 1.5–8.3) higher risk of muscle-related toxicity, respectively."""	hmg coa reductase inhibitors
1448531034	rs7634096	PMID:27450232	P2RY12	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.809	64	313	East Asian	Efficacy	false		clopidogrel
1449163372	rs1799853	PMID:29273767	CYP2C9	Allele C is not associated with risk of Stroke when treated with Vitamin K antagonists in people with Atrial Fibrillation as compared to allele T.	no	= 0.885	33		Unknown	Efficacy	false	No association was seen between this SNP and risk for early ischemic stroke (within 2 years under vitamin K antagonist (VKA) treatment).	Vitamin K antagonists
1444704529	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25877345	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) are not associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	no	=  0.089			Unknown	Toxicity	false	"Compared to the Asian studies were all subjects underwent PCI, the studies in the Western population had a lower number of patients undergoing PCI. The exclusion of of Pare et al, the analysis showed significantly higher risk for MACE in Western subgroup, with RR being 1.57, 95% CI: 1.11–2.11, P=0.01. Twelve studies reported PMs vs. EMs, PMs vs. IMs, and 14 studies reported IMs vs. EMs. The analysis was further stratified the studies by race. The number of patients per race or CYP2C19 metabolizer group was not reported. The outcome analyzed is recurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke."	clopidogrel
1448531012	rs1491974	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.511	64	313	East Asian	Efficacy	false		clopidogrel
1449163379	rs1057910	PMID:29273767	CYP2C9	Allele A is not associated with risk of Stroke when treated with Vitamin K antagonists in people with Atrial Fibrillation as compared to allele C.	no	= 0.889	33		Unknown	Efficacy	false	No association was seen between this SNP and risk for early ischemic stroke (within 2 years under vitamin K antagonist (VKA) treatment).	Vitamin K antagonists
1452514944	rs1128503	PMCID:PMC11194867	ABCB1	Genotype GG is associated with decreased platelet reactivity when treated with clopidogrel in people with Stroke as compared to genotypes AA + AG.	yes	= 0.006	128		Unknown	Efficacy	false	"Alleles complemented. ""A significant association was found between platelet reactivity (as seen on VerifyNow PRU) and ABCB1 C1236T (p = 0.031)."" ""However, in the homozygous wildtype group, a median VerifyNow value of < 95 PRU was found, which corresponds to bleeding risk with clopidogrel administration."" ""Study found that subjects with homozygote wildtype (CC) had 3.76 (95% CI 1.408–10.069) higher probability of bleeding risk compared to heterozygote and homozygote variant (CT/TT)."""	clopidogrel
769169358	rs699	PMID:14643574	AGT	Genotype GG is associated with decreased risk of Stroke when treated with Ace Inhibitors, Plain in people with Hypertension as compared to genotypes AA + AG.	yes	= 0.02	116	717	Multiple groups	Efficacy	false		Ace Inhibitors, Plain
1448531023	rs9859538	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.849	64	313	East Asian	Efficacy	false		clopidogrel
1446900004	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMCID:PMC4599525	CYP2C19	CYP2C19 *2 is not associated with likelihood of Hemorrhage when exposed to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1 + *17.	not stated		493		Multiple groups	Efficacy,Other	false	The authors grouped patients with the *1/*1, *1/*17, and *17/*17 diplotypes and compared them to patients with the *1/*2, *2/*2 genotypes as extensive, ultra rapid metabolizers, intermediate metabolizers, and poor metabolizers, respectively. Primary safety outcome was major bleeding (serious or life threatening bleeding requiring transfusion of blood or surgery). Results are for patients randomized to receive aspirin and clopidogrel (dual anti platelet therapy). The results were not significant for the any group and there were no events in the African-American group.	aspirin; clopidogrel
1452473224	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:37607302	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of Stroke when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.028	1141		Unknown	Efficacy	false		clopidogrel
1448617284	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8; CYP2C19*17	PMID:27806998	CYP2C19	CYP2C19 *2 + *3 + *8 are not associated with risk of Hemorrhage when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	no	= 0.59	3522		Multiple groups	Toxicity	false		clopidogrel
827639412	rs11039149	PMCID:PMC3093636	NR1H3	Allele G is associated with decreased risk of Myocardial Infarction and Stroke when treated with atenolol and verapamil in people with Coronary Artery Disease and Hypertension as compared to allele A.	yes	= 0.003	297		Unknown	Efficacy	false	The study selected approximately 2.5 controls per case. Risk assessment is done as primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke.	atenolol; verapamil
1451454882	rs12041331	PMID:34075782	PEAR1	Genotypes AA + AG is associated with increased likelihood of Myocardial Infarction, Myocardial Ischemia or Stroke when treated with Platelet aggregation inhibitors excl. heparin in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.03	8236		Multiple groups, Studies from China, Germany, Egypt	Efficacy	false	Meta-analysis of studies of patients with variety of coronary artery diseases including ACS/SCAD + PCI, patients receiving standard antiplatelet therapies (ie. most likely aspirin plus clopidogrel but not specified).	Platelet aggregation inhibitors excl. heparin
1449163330	rs2108622	PMID:29273767	CYP4F2	Genotype TT is associated with increased risk of Stroke when treated with Vitamin K antagonists in people with Atrial Fibrillation as compared to genotypes CC + CT.	yes	= 0.019	33		Unknown	Efficacy	false	Increased risk for early ischemic stroke (within 2 years under vitamin K antagonist (VKA) treatment). The authors also note that the average dose or VKAs was higher for patients with the TT genotype as compared to the CC or CT genotype (p=0.075). Please note that alleles have been complemented to the plus chromosomal strand.	Vitamin K antagonists
1448531056	rs16863336	PMID:27450232	P2RY12	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.145	64	313	East Asian	Efficacy	false		clopidogrel
1451454891	rs2768759	PMID:34075782	PEAR1	Genotype AA is associated with increased likelihood of Myocardial Infarction, Myocardial Ischemia or Stroke when treated with Platelet aggregation inhibitors excl. heparin in people with Coronary Artery Disease as compared to genotypes AC + CC.	yes	= 0.03	773		Multiple groups, Studies from China, Germany,	Efficacy	false	Meta-analysis of studies of patients with variety of coronary artery diseases including ACS/SCAD + PCI, patients receiving standard antiplatelet therapies (ie. most likely aspirin plus clopidogrel but not specified).	Platelet aggregation inhibitors excl. heparin
1448531069	rs12497330	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.499	64	313	East Asian	Efficacy	false		clopidogrel
1446899985	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMCID:PMC4599525	CYP2C19	CYP2C19 *2 is associated with increased likelihood of Stroke when exposed to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1 + *17.	not stated		493		Multiple groups	Efficacy,Other	false	The authors grouped patients with the *1/*1, *1/*17, and *17/*17 diplotypes and compared them to patients with the *1/*2, *2/*2 genotypes as extensive, ultra rapid metabolizers, intermediate metabolizers, and poor metabolizers, respectively. Primary outcome was time to recurrent stroke (ischemic or hemorrhagic).  Results are for patients randomized to receive aspirin and clopidogrel (dual anti platelet therapy). The results were not significant for the whole group but were significant for the White sub-group analysis. There were no events in the Hispanic group.	aspirin; clopidogrel
827639418	rs12221497	PMCID:PMC3093636	NR1H3	Allele A is associated with decreased risk of Myocardial Infarction and Stroke when treated with verapamil in people with Coronary Artery Disease and Hypertension as compared to allele G.	yes	= 0.016	297		Unknown	Efficacy	false	The study selected approximately 2.5 controls per case. The risk assessment was for primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke.	verapamil
1452433341	rs2244613	PMID:38525959	CES1	Genotypes GG + GT is not associated with decreased risk of Hemorrhage when treated with dabigatran in people with Stroke as compared to genotype TT.	no	= 0.602	432		Unknown	Metabolism/PK	false	"""The prevalence of carriers of CES1 variant allele was 88.0% in the bleeding group compared with 66.6% in controls "" ""We did not see any significant risk in our cohort for carriers of CES1 rs2244613 variant allele (see in more detail Table 4). """	dabigatran
1449577814	rs7196161	PMID:29986700	VKORC1	Allele A is associated with dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism, Stroke and Venous Thrombosis as compared to allele G.	not stated		159	163	Multiple groups, Singapore: Chinese, Malay, Indian, Other	Dosage	false	used in a study comparing genotype-guided dosing vs conventional for warfarin initiation. Alleles complemented to plus chromosomal strand. Direction of effect not explicitly stated.	warfarin
1448531045	rs12487835	PMID:27450232	P2RY12	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.415	64	313	East Asian	Efficacy	false		clopidogrel
1451454903	rs12566888	PMID:34075782	PEAR1	Genotypes GT + TT is not associated with increased likelihood of Myocardial Infarction, Myocardial Ischemia or Stroke when treated with Platelet aggregation inhibitors excl. heparin in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.08	6580		Multiple groups, Studies from China, Germany	Efficacy	false	Meta-analysis of studies of patients with variety of coronary artery diseases including ACS/SCAD + PCI, patients receiving standard antiplatelet therapies (ie. most likely aspirin plus clopidogrel but not specified).	Platelet aggregation inhibitors excl. heparin
1449163356	rs9934438	PMID:29273767	VKORC1	Allele A is not associated with risk of Stroke when treated with Vitamin K antagonists in people with Atrial Fibrillation as compared to allele G.	no	= 0.159	33		Unknown	Efficacy	false	No association was seen between this SNP and risk for early ischemic stroke (within 2 years under vitamin K antagonist (VKA) treatment). Please note that alleles have been complemented to the plus chromosomal strand.	Vitamin K antagonists
1452370860	rs1801133	PMID:38287840	MTHFR	Allele A is associated with decreased clinical benefit to vitamin b12 and folic acid in people with Hyperhomocysteinemia and Stroke as compared to allele G.	yes	= 0.0015	96	162	Unknown	Efficacy	false	Full text was unavailable, annotation made using abstract.	vitamin b12 and folic acid
1448602391	rs9923231	PMCID:PMC5207541	VKORC1	Genotypes CT + TT is associated with increased risk of Hemorrhage or Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation or venous thromboembolism.	yes	= 0.025	120	120	Unknown	Toxicity	false		acenocoumarol; warfarin
1448530963	rs6798347	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.405	64	313	East Asian	Efficacy	false		clopidogrel
1451633600	rs4244285	PMID:34954768	CYP2C19	Allele A is associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to allele G.	yes	= 0.037	106	202	East Asian	Efficacy	false	"CYP2C19*2 (rs4244285) A allele was significantly higher in HPR (high platelet reactivity group) vs NPR (normal platelet reactivity). ""Patients with , inhibition of platelet aggregation IPA <30% were considered as clopidogrel high on-treatment platelet reactivity (HPR) group"""	aspirin; clopidogrel
1448530973	rs1907637	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.946	64	313	East Asian	Efficacy	false		clopidogrel
1448617237	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8; CYP2C19*17	PMID:27806998	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke when treated with clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	< 0.001	4762		Multiple groups	Efficacy	false	"Metaanalysis with 4762 patients from 15 studies showed that ""Carriers of CYP2C19 loss-of-function alleles (*2, *3, and *8) were at increased risk of stroke in comparison with noncarriers (12.0% versus 5.8%; risk ratio, 1.92, 95% confidence interval, 1.57–2.35; P<0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles than in noncarriers."""	clopidogrel
1448530954	rs6798637	PMID:27450232	P2RY12	Allele G is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele C.	no	= 0.792	64	313	East Asian	Efficacy	false		clopidogrel
1448530999	rs4603933	PMID:27450232	P2RY12	Allele G is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.549	64	313	East Asian	Efficacy	false		clopidogrel
1448276279	rs9934438	PMID:25989350	VKORC1	Allele A are associated with dose of warfarin in people with Stroke.	not stated		210		European	Dosage	false	This study assessed the clinical application of genotype-guided dosing of warfarin. The algorithm used to guide dose of warfarin included this variant.	warfarin
1448602417	CYP2C9*1; CYP2C9*3	PMCID:PMC5207541	CYP2C9	CYP2C9 *3 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	yes	= 0.002	120	120	Unknown	Toxicity	false		acenocoumarol; warfarin
1448617264	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8; CYP2C19*17	PMID:27806998	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	= 0.01	3778		Multiple groups	Efficacy	false	"Metaanalysis showed that ""Carriers of CYP2C19 loss-of-function alleles (*2, *3, and *8) were at increased risk of stroke in comparison with noncarriers (12.0% versus 5.8%; risk ratio, 1.92, 95% confidence interval, 1.57–2.35; P<0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles than in noncarriers."""	clopidogrel
1451633640	rs168753	PMID:34954768	F2R	Allele T is associated with decreased platelet reactivity when treated with aspirin and clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to allele A.	yes	= 0.015	106	202	East Asian	Efficacy	false	"""minor allele T of SNP rs168753 in F2R (P = 0.017) was significantly associated with normal platelet reactivity from clopidogrel-aspirin therapy"" higher in NPR (normal platelet reactivity) vs HPR (high platelet reactivity group). ""Patients with inhibition of platelet aggregation IPA <30% were considered as clopidogrel high on-treatment platelet reactivity (HPR) group"""	aspirin; clopidogrel
1448602404	CYP2C9*1; CYP2C9*2	PMCID:PMC5207541	CYP2C9	CYP2C9 *2 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	yes	= 0.002	120	120	Unknown	Toxicity	false		acenocoumarol; warfarin
1183689466	rs6025	PMID:15946211	F5	Genotypes CT + TT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	no		179	757	Unknown	Toxicity	false	Women who carry the Factor V Leiden (FVL) mutation and are taking oral contraceptives (OCs) have an odds ratio (OR) of 11.2 for ischemic stroke, as compared to non-carriers of the FVL mutation who are not taking any OCs. Women taking OCs without the FVL mutation have an increased risk for ischemic stroke as compared to those not taking OCs (OR in this study of 2.6). No significant increase in risk for ischemic stroke was seen in women with FVL who are not taking OCs, as compared to non-carriers (OR in this study of 0.4, non-significant). However, it is likely that the increased OR for women with FVL taking OCs, as compared to the OR for women taking OCs without the FVL mutation, is due to the cumulative effect of both OCs and the FVL mutation on risk for ischemic stroke. Cases had experienced ischemic stroke, controls had not.	hormonal contraceptives for systemic use
1452508900	CYP2C9*1; CYP2C9*2	PMID:38907686	CYP2C9	CYP2C9 *2 is associated with increased likelihood of international normalized ratio variability (inr-var) when treated with acenocoumarol in people with Stroke as compared to CYP2C9 *1/*1.	yes	= 0.03	82	75	Central/South Asian	Efficacy	false	"In univariate analysis ""CYP2C9*2 gene was related to unstable INR."" but not in multivariate analysis."	acenocoumarol
1448276267	CYP2C9*2; CYP2C9*3	PMID:25989350	CYP2C9	CYP2C9 *2 + *3 are associated with dose of warfarin in people with Stroke.	not stated		210		European	Dosage	false	This study assessed the clinical application of genotype-guided dosing of warfarin. The algorithm used to guide dose of warfarin included these variants.	warfarin
1446908484	CYP2C19*1; CYP2C19*2	PMCID:PMC4413440	CYP2C19	CYP2C19 *2 is associated with increased risk of Stroke when treated with clopidogrel in people with Cerebrovascular Disorders as compared to CYP2C19 *1/*1.	yes	< 0.0001	51		Unknown	Efficacy	false	*2 carriers were more likely to suffer from a recurring ischemic stroke during treatment after Acute Ischemic Cerebrovascular Disease. Patients were monitored for at least 1 year.  *2/*2 (n=2), *1/*2 (n=13), and *1/*1 (n=36), one *2/*2 and two *1/*2 suffered from recurrent stroke and switched to warfarin	clopidogrel
1448530986	rs10935842	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.927	64	313	East Asian	Efficacy	false		clopidogrel
1448530896	rs1062535	PMID:27450232	PEAR1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.900	64	313	East Asian	Efficacy	false		clopidogrel
1447521217	rs71647871	PMCID:PMC4915569	CES1	Allele T is not associated with decreased risk of Ischemic Attack, Transient, Stroke, Myocardial Infarction or Death when treated with aspirin and clopidogrel as compared to allele C.	no	= 0.12	188		Multiple groups	Efficacy	false	within 12 months in patients with symptomatic intracranial atherosclerotic disease.	aspirin; clopidogrel
1447949770	rs776746	PMCID:PMC5098919	CYP3A5	Genotypes CC + CT are associated with increased resistance to clopidogrel in people with Stroke as compared to genotype TT.	yes	= 0.016	375		East Asian	Efficacy	false	Frequency of CC+TC genotypes was significantly higher in clopidogrel-resistant patients than in clopidogrel-sensitive patients.	clopidogrel
1448530904	rs1062535	PMID:27450232	PEAR1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele del.	no	= 0.900	64	313	East Asian	Efficacy	false		clopidogrel
1451915780	rs4244285	PMID:36215918	CYP2C19	Genotypes AA + AG is associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to genotype GG.	yes	< 0.05	752		East Asian	Efficacy	false	"""The risk of stroke recurrence in patients with GA/AA genotype at CYP2C19 * 2 locus was significantly higher than that with GG genotype."""	clopidogrel
1452486940	rs4693075	PMCID:PMC11106472	COQ2	Genotypes CG + GG is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Stroke as compared to genotype CC.	yes	< 0.001	56	632	East Asian	Efficacy	false	"""Wild-type allele (G) carriers of COQ2 rs4693075 had a higher risk of SRM than mutant-type homozygote carriers (CC) (13.2% vs. 6.3%, p = 0.006)."" Caution, this is a G>C variant in a gene on the minus strand. The discussion mentions conflicting results with this variant but does not clarify the issue of strand."	hmg coa reductase inhibitors
1183689500	rs6025	PMID:16769590	F5	Genotype CT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	yes		119	293	European	Toxicity	false	Women heterozygous for the Factor V Leiden (FVL) mutation and taking oral contraceptives (OCs) have an odds ratio (OR) of 12.9 for ischemic stroke as compared to non-carriers of the FVL mutation who are not taking any OCs.  Women taking OCs without the FVL mutation have an increased risk for ischemic stroke as compared to those not taking OCs (OR in this study of 2.1). No significant increase in risk for ischemic stroke was seen in women with FVL who are not taking OCs, as compared to non-carriers (OR in this study of 1.4, non-significant). However, it is likely that the increased OR for women with FVL taking OCs, as compared to the OR for women taking OCs without the FVL mutation, is due to the cumulative effect of both OCs and the FVL mutation on risk for ischemic stroke. Cases had experienced ischemic stroke, controls had not.	hormonal contraceptives for systemic use
1447949788	CYP2C19*1; CYP2C19*2	PMCID:PMC5098919	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	= 0.003	37	326	East Asian	Toxicity	false	The frequency of primary adverse events was higher in patients who carry the *2 genotype than in patients without. Cox regression analysis also revealed that CYP2C19*2 is an independent risk factors for primary adverse events (HR=2.01, p=0.006, 95%CI:1.46-5.66).	clopidogrel
769169226	rs699	PMID:14643574	AGT	Genotype GG is associated with decreased risk of Stroke when treated with Ace Inhibitors, Plain in people with Hypertension.	yes		116	717	"Multiple groups, Controls- 92.3 % White; Stroke- 94.0 % White.  "	Efficacy	false	Non-fatal stroke was assessed.  Comparison is with users of other antihypertensive medications.	Ace Inhibitors, Plain
1451915800	rs4986893	PMID:36215918	CYP2C19	Genotype AG is not associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to genotype GG.	no	> 0.05	653		East Asian	Efficacy	false	"""no significant difference in the risk of stroke recurrence between CYP2C19 * 3 GA and GG genotype patients treated with clopidogrel"". ""Only one case of recurrence with CYP2C19 * 3AA genotype was reported in 5 studies."""	clopidogrel
1448530880	rs4244285	PMID:27450232	CYP2C19	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.742	64	313	East Asian	Efficacy	false		clopidogrel
1448530888	rs762551	PMID:27450232	CYP1A2	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele C.	no	= 0.793	64	313	East Asian	Efficacy	false		clopidogrel
1447949779	rs776746	PMCID:PMC5098919	CYP3A5	Genotypes CC + CT are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to genotype TT.	yes	= 0.018	37	326	East Asian	Toxicity	false	The frequency of primary adverse events was higher in patients who carry the CC or CT genotype than in patients who carry the TT genotype.	clopidogrel
1450044109	rs35068180	PMCID:PMC3859235	MMP3	Genotype del/del is associated with decreased risk of Stroke when treated with lisinopril in people with Hypertension.	yes	= 0.009	6329	10554	Multiple groups	Efficacy	false	as compared with participants treated with chlorthalidone with the AA genotype. Each combination of genotype and drug treatment was compared with a common reference group, AA individuals randomized to chlorthalidone. Compared with participants treated with chlorthalidone with the AA genotype, individuals with the AA genotype randomized to lisinopril had higher stroke rates (hazard ratio=1.32; 95% CI, 1.08 to 1.61, p=0.007) and del/A individuals taking lisinopril had lower stroke rates (hazard ratio(interaction)=0.74; 95% CI, 0.53-1.04; p(interaction)=0.08), whereas del/del individuals taking lisinopril had the lowest stroke rate (hazard ratio(interaction)=0.51; 95% CI, 0.31 to 0.85; p(interaction)=0.009).	lisinopril
1452371762	rs1801253	PMCID:PMC10827366	ADRB1	Genotype CC is associated with increased likelihood of Stroke when treated with Antihypertensives, Beta Blocking Agents or diuretics in people with Hypertension as compared to genotypes CG + GG.	yes	= 0.012	816	28845	East Asian	Efficacy	false	"""The results revealed that CC (vs GC + GG) of the ADRB1 (1165G > C) gene was associated with stroke occurrence in nondiabetic and noncoronary populations of hypertensive patients (OR: 1.20, 95% CI: 1.03–1.41; OR: 1.30, 95% CI: 1.09–1.56), in hypertensive patients who took BBs (OR: 2.43, 95% CI: 1.08–5.47; OR: 1.17, 95% CI: 1.010–1.348) or diuretics (OR: 1.707, 95% CI: 1.226–2.376) (Figure 2)."""	Antihypertensives; Beta Blocking Agents; diuretics
1449751756	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:29520080	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 are associated with decreased response to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	= 0.03	1476		Unknown	Efficacy	false	Patients who were classified as carrying loss-of-function (LOF) alleles *2 and *3 had an increased risk for hemorrhagic stroke, ischemic stroke and combined vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death) during a 90-day follow-up period when treated with clopidogrel and aspirin as compared to those without LOF alleles. The authors also found that when separating patients into 5 quintiles based on their eGFR (kidney function), results in Quintile 5 (eGFR<75 ml/min/1.73^2; n=296) were also significant for all three outcome measures (p=0.02, HR=7.39 (1.44-37.95) for all), but the results in Quintiles 1-4 were not. No significant association with bleeding events was found.	aspirin; clopidogrel
1448530928	rs1799983	PMID:27450232	NOS3	Allele G is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.414	64	313	East Asian	Efficacy	false		clopidogrel
1451915820	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:36215918	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	< 0.05	1250		East Asian	Efficacy	false	"""IM(*1/*2 or *1/*3) and PM(*2/*3, *2/*2, *3/*3)."" ""the risk of stroke recurrence between CYP2C19 IM+PM, IM, PM and EM(P<0.05),while there was no significant difference between PM and IM(P>0.05)"""	clopidogrel
981755436	rs669	PMID:23280790	A2M	Genotype TT is associated with increased risk of hemorrhagic transformation when treated with Enzymes in people with Stroke as compared to genotypes CC + CT.	yes	= 7.44E-6	885		European	Toxicity	false	Enzymes refers to tissue plasminogen activator (t-PA) treatment. Patients belonged to either cohort A (n=531) or B (n=354). Bonferroni correction was applied, and the level of statistical significance was set at p < 3.57E-4. No significant association was seen within cohort B. Please note alleles have been complemented to the plus chromosomal strand.	Enzymes
1449577166	CYP2C9*3	PMID:29986700	CYP2C9	CYP2C9 *3 is associated with dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism, Stroke and Venous Thrombosis.	not stated		159	163	Multiple groups, Singapore: Chinese, Malay, Indian, Other	Dosage	false	used in a study comparing genotype-guided dosing vs conventional for warfarin initiation.	warfarin
1448530941	rs16863356	PMID:27450232	MED12L	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.771	64	313	East Asian	Efficacy	false		clopidogrel
1448604391	CYP2C19*1; CYP2C19*2	PMID:26873108	CYP2C19	CYP2C19 *2/*2 is associated with increased resistance to clopidogrel in people with Acute coronary syndrome and Stroke as compared to CYP2C19 *1/*1.	yes	= 0.011	189		European	Efficacy	false		clopidogrel
1448530912	rs12041331	PMID:27450232	PEAR1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.924	64	313	East Asian	Efficacy	false		clopidogrel
1446899082	CYP2C19*1; CYP2C19*2; CYP2C19*4; CYP2C19*17	PMID:26265231	CYP2C19	CYP2C19 *2 + *4 are not associated with risk of Death, Ischemic Attack, Transient, Stroke or Thrombosis when treated with clopidogrel as compared to CYP2C19 *1 + *17.	no	= 0.90	1394		Unknown	Other	false	"Incidence of these cardiovascular events 1 year after stent placement was not different between rapid and slow metabolizers (32.3% vs 32.7%, respectively). The authors use the term ""slow metabolizer"" to mean any individuals carrying the *2, *4 alleles and do not differentiate between homo- and heterozygotes. The authors use the term ""rapid metabolizer"" to mean any individuals NOT carrying the *2 or *4 alleles, and include individuals carrying the *17 allele. They do not differentiate between homo- and heterozygotes. Patients were administered clopidogrel before stent implantation and were randomized to a group with monitoring by platelet reactivity or a group without monitoring."	clopidogrel
1183689524	rs1799963	PMID:16769590	F2	Genotypes AA + AG is not associated with risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype GG.	no		119	293	European	Toxicity	false	Women homozygous or heterozygous for the G20210A prothrombin (PT) mutation and taking oral contraceptives (OCs) do not have a significantly higher risk for ischemic stroke than non-carriers of the PT mutation who are not taking any OCs. Cases had experienced ischemic stroke, controls had not.	hormonal contraceptives for systemic use
981802814	rs662	PMID:23346768	PON1	Allele C is not associated with maximum platelet aggregation (MPA) or the anti-platelet effect of clopidogrel in Chinese stroke patients when treated with clopidogrel in people with Stroke as compared to allele T.	no	= 0.91	170		East Asian	Efficacy	false		clopidogrel
1448530920	rs1126643	PMID:27450232	ITGA2	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.930	64	313	East Asian	Efficacy	false		clopidogrel
1447949708	rs2242480	PMCID:PMC5098919	CYP3A4	Genotypes CT + TT is not associated with resistance to clopidogrel in people with Stroke as compared to genotype CC.	no	= 0.91	375		East Asian	Efficacy	false		clopidogrel
981755456	rs1801020	PMID:23280790	F12	Genotype GG is associated with increased risk of Death when treated with Enzymes in people with Stroke as compared to genotypes AA + AG.	yes	= 1.85E-4	885		European	Toxicity	false	Enzymes refers to tissue plasminogen activator (t-PA) treatment. Death refers to in-hospital mortality. Patients belonged to either cohort A (n=531) or B (n=354). Bonferroni correction was applied, and the level of statistical significance was set at p < 3.57E-4. A significant association was only seen within cohorts A and B combined. Please note alleles have been complemented to the plus chromosomal strand.	Enzymes
1448531088	rs2046934	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.197	64	313	East Asian	Efficacy	false		clopidogrel
1452502360	CYP2C19*1; CYP2C19*2; CYP2C19*9; CYP2C19*13; CYP2C19*17	PMID:38874073	CYP2C19	CYP2C19 *1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased risk of major adverse cardiac events (mace), Death, Myocardial Infarction, Stroke or Angina, Unstable when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultrarapid metabolizer and rapid metabolizer phenotype) .	yes	= 0.008	567		African American/Afro-Caribbean	Efficacy	false	"""Overall, 67 (11.8%) patients experienced an MAE during follow‐up. MAE occurred at a significantly higher rate in clopidogrel‐treated IM/PMs versus NM/RM/UMs (35.1 versus 15.9 per 100 person‐years, respectively; adjusted HR, 2.00 [95% CI, 1.20–3.33], P=0.008) (Table 2, Figure 1A). The secondary outcome of MACE occurred in 47 (8.3%) patients during follow‐up. Like MAE, MACE occurred at a significantly higher rate among IM/PMs versus NM/RM/UMs (24.9 versus 11.1 per 100 person‐years, respectively; adjusted HR, 2.06 [95% CI, 1.12–3.80], P=0.020) (Table 2, Figure 1B). "" From S1 ""The IM phenotypes consisted of the following genotypes: *1/*2 (82, 14.5%, *2/917 (32, 5.6%), *1/*9 (2,0.4%), *2/*13 (1, 0.2%), and $9/*17 (1, 0.2%). All PM phenotypes consisted of the *2/*2 genotype (7, 1.2%)."" ""The primary outcome was a composite of MAE, which was defined as all‐cause death, MI, ischemic stroke, stent thrombosis, or revascularization for unstable angina within 12 months following the index PCI. The secondary outcome, major adverse cardiovascular events (MACE), was the composite of cardiovascular death, MI, stent thrombosis, or ischemic stroke within 12 months after the index PCI."""	clopidogrel
1451911749	rs1617640	PMCID:PMC9502050	EPO	Allele A is not associated with likelihood of Coronary Artery Disease, Stroke, Myocardial Infarction or systolic blood pressure as compared to allele C.	no	= 0.38	678320		Unknown	Other	false	The cis-EPO SNP rs1617640 was used as an instrument in two-sample Mendelian randomization as a genetic predictor for therapeutically altered EPO levels.  The likelihood of genetic associations between 1 SD higher endogenous EPO levels (equivalent to 5.1 IU/L) and increased odds of cardiovascular disease (CVD) or levels of clinical markers predisposing to CVD were reported.	
1452023900	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC9931738	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	< 0.001	93	119	East Asian	Efficacy	false	this was greater for the *2/*2+*2/*3 than *1/*2+*1/*3. Two patients with *17 (one was *2/*17 and other was *3/*17) were excluded from analysis.	clopidogrel
1447521170	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8	PMCID:PMC4915569	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with decreased risk of Ischemic Attack, Transient, Death, Stroke or Myocardial Infarction when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.0101	188		Multiple groups	Efficacy	false	"within 12 months in patients with symptomatic intracranial atherosclerotic disease.  ""Variant alleles of CYP2C19 (*2, *3, *8) were associated with lower odds of the primary and secondary composite endpoints. However, the direction of the association was opposite of what is expected based on this SNP. This may reflect an incomplete understanding of this genetic variation and its effect in symptomatic ICAD and warrants further investigations."""	aspirin; clopidogrel
827639426	rs2279238	PMCID:PMC3093636	NR1H3	Allele T is associated with increased risk of Myocardial Infarction and Stroke when treated with verapamil in people with Coronary Artery Disease and Hypertension as compared to allele C.	yes	= 0.031	297		Unknown	Efficacy	false	The study selected approximately 2.5 controls per case. The risk assessment was for primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke	verapamil
1447949723	rs1934980	PMCID:PMC5098919	CYP2C8	Genotypes AA + AG is not associated with resistance to clopidogrel in people with Stroke as compared to genotype GG.	no	= 0.91	375		East Asian	Efficacy	false		clopidogrel
1447949716	rs17110453	PMCID:PMC5098919	CYP2C8	Genotypes AC + CC is not associated with resistance to clopidogrel in people with Stroke as compared to genotype AA.	no	= 0.68	375		East Asian	Efficacy	false		clopidogrel
1450044086	rs35068180	PMCID:PMC3859235	MMP3	Genotype AA is associated with increased risk of Stroke when treated with lisinopril in people with Hypertension.	yes	= 0.007	6329	10554	Multiple groups	Efficacy	false	as compared with participants treated with chlorthalidone with the AA genotype. Each combination of genotype and drug treatment was compared with a common reference group, AA individuals randomized to chlorthalidone. Compared with participants treated with chlorthalidone with the AA genotype, individuals with the AA genotype randomized to lisinopril had higher stroke rates (hazard ratio=1.32; 95% CI, 1.08 to 1.61, p=0.007) and del/A individuals taking lisinopril had lower stroke rates (hazard ratio(interaction)=0.74; 95% CI, 0.53-1.04; p(interaction)=0.08), whereas del/del individuals taking lisinopril had the lowest stroke rate (hazard ratio(interaction)=0.51; 95% CI, 0.31 to 0.85; p(interaction)=0.009).	lisinopril
769176324	rs20417	PMID:15138244	PTGS2	Genotypes CG + GG are associated with decreased risk of Stroke as compared to genotype CC.	yes	< 0.001	864	864	European		false	(significance stated for CC+CG, but gene on minus strand).	
769176580	rs20417	PMCID:PMC2244790	PTGS2	Allele G is associated with increased risk of Stroke as compared to allele C.	yes	= 0.031	114	303	African American/Afro-Caribbean		false	"NB: C/G SNP in gene on minus strand, paper reports C association therefore annotated as G on plus strand.  Association not seen in Caucasians."	
1444704705	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25529343	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased response to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	< 0.001	76		East Asian	Efficacy	false	Response as defined by increase in early ischemic lesion recurrence detected on diffusion-weighted imaging. Early ischemic lesion recurrence were observed more frequently in IMs (*1/*2 and *1/*3) than in EMs although not significantly ( P = .053)	clopidogrel
1444704450	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25877345	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.001			Unknown	Toxicity	false	"Twenty-two studies involving a total of 25564 CAD patients treated with clopidogrel contributed to this analysis. But the analysis was further stratified the studies by race. The number of patients per race was not reported. The outcome analyzed is recurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke."	clopidogrel
1448531080	rs12637988	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.295	64	313	East Asian	Efficacy	false		clopidogrel
1448530614	rs4986893	PMID:27450232	CYP2C19	Allele A is associated with increased risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	yes	= 0.007	64	313	East Asian	Efficacy	false		clopidogrel
1447521191	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8	PMCID:PMC4915569	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with decreased risk of Ischemic Attack, Transient, Stroke or Death when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.078	188		Multiple groups	Efficacy	false	"in patients with symptomatic intracranial atherosclerotic disease. ""Variant alleles of CYP2C19 (*2, *3, *8) were associated with lower odds of the primary and secondary composite endpoints. However, the direction of the association was opposite of what is expected based on this SNP. This may reflect an incomplete understanding of this genetic variation and its effect in symptomatic ICAD and warrants further investigations."""	aspirin; clopidogrel
1452287600	rs12041331	PMCID:PMC10605279	PEAR1	Genotypes AA + AG is associated with increased risk of Hemorrhage when treated with aspirin, clopidogrel or ticagrelor in people with Stroke as compared to genotype GG.	yes	= 0.009	372		Unknown	Toxicity	false	"Payients from PRINCE trial randomly assigned to aspirin+clopidogrel or aspirin+ticagrelor. ""those carrying the ‘a’ allele at rs12041331 were more likely to experience bleeding event"", also significant in logistic regression."	aspirin; clopidogrel; ticagrelor
1452433267	rs4148738	PMID:38525959	ABCB1	Genotypes CC + CT is associated with increased concentrations of dabigatran in people with Stroke as compared to genotype TT.	no	= 0.022	432		Unknown	Metabolism/PK	false	"""The adjusted through plasmatic level of dabigatran among the ABCB1 genotypes was also significantly different, F(2, 428) = 4.742, P = 0.009, partial η2 = 0.022. Post hoc analysis Bonferroni adjustment showed statistically significantly greater plasmatic levels of dabigatran in homozygotes for rs4148738 versus the WT (mean difference of 21.992; 95% CI, 2.337–41.647 ng/mL, P = 0.022) and heterozygotes (mean difference of 22.498; 95% CI, 4.131–40.865 ng/mL, P = 0.010). Variant allele carriers grouped together did not have significantly higher dabigatran plasmatic levels compared with noncarriers (mean difference of 5.335; 95% CI, −17.043 to 6.373 ng/mL, P = 0.371) (see also Table 2)."""	dabigatran
1184747903	rs12143842	PMCID:PMC4189974		Allele C is associated with decreased risk of Stroke when treated with amlodipine in people with Hypertension.	not stated		436		African American/Afro-Caribbean	Efficacy	false	as compared to treatment with chlorthalidone or lisinopril.	amlodipine
1452287607	rs2768759	PMCID:PMC10605279	PEAR1	Genotype AC is associated with increased risk of Hemorrhage when treated with aspirin, clopidogrel or ticagrelor in people with Stroke as compared to genotype AA.	yes	= 0.037	368		Unknown	Toxicity	false	"Payients from PRINCE trial randomly assigned to aspirin+clopidogrel or aspirin+ticagrelor. ""Risk factors such as the ticagrelor and aspirin antiplatelet strategy, the initial event of mild stroke, and the presence of the AA + AG genotype at rs12041331 and the CA genotype at rs2768759 show a positive correlation with bleeding events. "" No CC homozygotes of rs2768759 were observed."	aspirin; clopidogrel; ticagrelor
1452433274	rs4148738	PMID:38525959	ABCB1	Genotypes CC + CT is associated with increased likelihood of Hemorrhage when treated with dabigatran in people with Stroke as compared to genotype TT.	yes	= 0.024	432		Unknown	Toxicity	false	"""We observed a significant risk of clinically relevant bleeding for the carriers of the ABCB1 rs4148738 allele (HR = 1.99, 95% CI, 1.10–3.59, P = 0.024). When we analyzed the data according to the allele count, this result was significant for homozygotes and nonsignificant for heterozygotes."""	dabigatran
1448097468	CYP2C19*1; CYP2C19*2	PMID:27233747	CYP2C19	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	= 0.018	375		East Asian	Efficacy	false	CYP2C19*2(rs4244285) variant was independently associated with clopidogrel resistance and risk of adverse events after adjusting covariates.	clopidogrel
1184747888	rs200148	PMCID:PMC4189974		Allele A is associated with increased risk of Stroke when treated with chlorthalidone in people with Hypertension.	not stated		436		African American/Afro-Caribbean	Efficacy	false	as compared to treatment with amlodipine or lisinopril	chlorthalidone
1444704497	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25877345	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	< 0.001			Multiple groups	Toxicity	false	"Twelve studies reported PMs vs. EMs, PMs vs. IMs, and 14 studies reported IMs vs. EMs. The analysis was further stratified the studies by race. The number of patients per race or CYP2C19 metabolizer group was not reported. The outcome analyzed is recurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke."	clopidogrel
1448530872	rs1045642	PMID:27450232	ABCB1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.214	64	313	East Asian	Efficacy	false		clopidogrel
1447949731	CYP2C9*1; CYP2C9*3	PMCID:PMC5098919	CYP2C9	CYP2C9 *1/*3 + *3/*3 is not associated with resistance to clopidogrel in people with Stroke as compared to CYP2C9 *1/*1.	no	= 0.37	375		East Asian	Efficacy	false		clopidogrel
1448530854	rs8192950	PMID:27450232	CES1	Allele G is associated with decreased risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	yes	= 0.029	64	313	East Asian	Efficacy	false		clopidogrel
1447949757	CYP2C19*1; CYP2C19*2	PMCID:PMC5098919	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	< 0.001	375		East Asian	Efficacy	false	Frequency of CYP2C19*2 (rs4244285) AA/AG genotypes was significantly higher in clopidogrel-resistant patients than in clopidogrel-sensitive patients.	clopidogrel
1447521206	CYP2C19*1; CYP2C19*17	PMCID:PMC4915569	CYP2C19	CYP2C19 *17 is not associated with decreased risk of Ischemic Attack, Transient, Stroke, Myocardial Infarction or Death when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.89	188		Multiple groups	Efficacy	false	within 12 months in patients with symptomatic intracranial atherosclerotic disease.	aspirin; clopidogrel
1448267942	rs9934438	PMCID:PMC4800352	VKORC1	Genotypes AG + GG are associated with increased dose of warfarin in people with Stroke as compared to genotype AA.	not stated	< 0.05	101		East Asian	Dosage	false	Warfarin dose was 6 mg/day in the one patient with the GG genotype, and 4.6+/-1.9 mg/day in the 17 patients with the AG genotype, as compared to 3.6+/-1.2 in patients with the AA genotype. Additionally, this study undertook the development of a warfarin pharmacogenetic dosing algorithm and then compared it against other dosing algorithms. This variant was included in the algorithm. Please note that alleles have been complemented to the plus chromosomal strand.	warfarin
1447949744	CYP2C19*1; CYP2C19*3	PMCID:PMC5098919	CYP2C19	CYP2C19 *1/*3 + *3/*3 are not associated with resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	no	= 0.24	375		East Asian	Efficacy	false		clopidogrel
1448267948	CYP2C9*3	PMCID:PMC4800352	CYP2C9	CYP2C9 *3 is associated with dose of warfarin in people with Stroke.	not stated		101		East Asian	Dosage	false	This study undertook the development of a warfarin pharmacogenetic dosing algorithm and then compared it against other dosing algorithms. This variant was included in the algorithm. However, note that there was no significant difference in stable warfarin dose between patients with the *1/*1 genotype (3.8+/1.4 mg/day) and the *1/*3 genotype (2.6+/-0.5 mg/day); only 4 patients carried the *3 allele.	warfarin
1452433260	rs2244613	PMID:38525959	CES1	Genotypes GG + GT is associated with decreased concentrations of dabigatran in people with Stroke as compared to genotype TT.	yes	= 0.003	432		Unknown	Metabolism/PK	false	"""When we considered all CES1 variant carriers together compared with the WT patients, the plasmatic levels were significantly lower (mean difference of 16.986; 95% CI, 5.794–28.178 ng/mL, P = 0.003) (see also Table 2)."""	dabigatran
1452487020	rs11548336	PMCID:PMC11106472	COQ3	Genotype TT is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Stroke as compared to genotypes CC + CT.	yes	< 0.05	56	632	East Asian	Efficacy	false	"""Patients carrying the TT genotype of rs11548336 and A allele of rs10849757 had a 1.9-fold (95% CI: 1.1–3.5) and 3.3-fold (95% CI: 1.5–8.3) higher risk of muscle-related toxicity, respectively."""	hmg coa reductase inhibitors